Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)

NCT05271526 | Completed

• 1 other identifier: D3250R00101
• Study Type: observational
• Target: 3
• Locations: 1 country
• Sites: 1

Brief Summary

Benralizumab is a humanised, afucosylated, monoclonal antibody against the interleukin (IL)-5 receptor (IL-5R) α subunit that induces direct, rapid, and near-complete depletion of eosinophils in blood, airway tissue, and bone marrow through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). This apoptotic process involves natural killer cells responsible for the controlled eosinophilic elimination. In the two pivotal phase III trials SIROCCO and CALIMA, benralizumab was well tolerated, significantly reduced asthma exacerbations by up to 51%, and improved lung function as well as disease control in patients with severe, uncontrolled asthma and blood eosinophil count of ≥ 300 cells/μL blood, receiving both ICS and LABA. According to the summary of product's characteristics (SmPC) of benralizumab in Russia, it can be used for an add-on maintenance treatment for adult patients with severe eosinophilic asthma. All patients enrolled in the BEST study will comply with the SmPC approved by the Russian Ministry of Health.

Conditions

Severe Eosinophilic Asthma

Outcome Measures

Primary Outcomes (2)

• To evaluate the change in patient asthma control after initiation of benralizumab in a real-world Russian setting

  Mean scores change from baseline in Asthma Control Questionnaire-5 (ACQ-5) after 8 weeks of treatment with benralizumab.

  Up to 6 month

• To evaluate the change in respiratory health-related quality of life in a real-world Russian setting

  Total scores change from baseline in St. George's Respiratory Questionnaire (SGRQ) after 8 weeks of treatment with benralizumab

  Up to 6 month

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study will recruit 59 male and female patients aged ≥ 18 years with severe, eosinophilic asthma who meet all inclusion criteria and none of the exclusion criteria (15% drop out). Approximately 10 centers across Russia will participate in the study. Only those centres that have experience with biologic treatment, can initiate treatment with benralizumab and have a good oversight on the severe asthma population (as in some settings the patients are referred for longer term stationary care to achieve asthma control) will be able to participate.

You may qualify if:

• Subject eligible for enrolment in the study and treatment for benralizumab according to the specific Russian label and in line with reimbursement condition must meet all the following criteria:
• Male or female patients older than 18 years with physician's confirmed diagnosis of severe, uncontrolled asthma.
• Asthma requiring high-dose ICS plus LABA as maintenance treatment.
• Minimum of 2 exacerbations in the last 12 months. Or 1 exacerbation in case that patient had been receiving oral glucocorticoid therapy for at least 6 continuous months directly before enrollment (equivalent to a prednisolone or prednisone dose of 7.5 to 40.0 mg per day)
• Documented peripheral blood eosinophil count ≥ 300 cells/μL or ≥150 cells/μL blood in case that patient had been receiving oral glucocorticoid therapy for at least 6 continuous months directly before enrollment (equivalent to a prednisolone or prednisone dose of 7.5 to 40.0 mg per day).
• Provision of signed written ICF indicating that they understand the purpose of the study and procedures required for participation in the study.
• Patients must be able and willing to read and comprehend written instructions and comprehend and complete the questionnaires required by the protocol (SGRQ, ACQ-5, PGIC and PGIS).

You may not qualify if:

• Patients who have previously received benralizumab prior to the start of the study.
• Documented lung diseases other than asthma, e.g. COPD, and not within reimbursed label, e.g pregnancy or lactation.
• Concomitant treatment with any other biologic for any indication or previous treatment with biology. Acceptable wash-out periods for other asthma biologics: ≥4 month or duration of 5 half-lives from last dose of previous biologic. We choose what is longer the 5 half-life or 4 months.
• Currently enrolled in an interventional clinical study in parallel, except:
• Patients being in parallel documented in a national asthma registry.
• Patients having completed any other clinical trial including those with biologic treatment ≥4 month or duration of 5 half-lives from last dose of previous biologic. We choose what is longer the 5 half-life or 4 months.
• An acute or chronic condition that, in the investigator's opinion, would limit the patients' ability to complete questionnaires or participate in this study or impact the interpretations of results.

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (1)

City clinical hospital No57

Moscow, 105077, Russia

Location

Related Links

• CSR Synopsis

MeSH Terms

Conditions

Pulmonary Eosinophilia

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hypereosinophilic Syndrome; Eosinophilia; Leukocyte Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2022
• First Posted: March 9, 2022
• Study Start: May 16, 2022
• Primary Completion: November 13, 2023
• Study Completion: November 13, 2023
• Last Updated: October 21, 2024

Record last verified: 2024-10

Locations

RU (1)